Caris Life Sciences (CAI) Retained Earnings (2025 - 2026)
Caris Life Sciences (CAI) posted quarterly Retained Earnings of -$2.5 billion for Q1 2026, down 181.14% quarter-over-quarter from $3.1 billion in Q4 2025.
Caris Life Sciences (CAI) Retained Earnings (2025 - 2026) Analysis & Trends
Caris Life Sciences' Retained Earnings history runs 2 years deep, the most recent figure standing at -$2.5 billion for Q1 2026.
- In Q1 2026, Retained Earnings changed N/A year-over-year to -$2.5 billion; the TTM figure through Mar 2026 stood at -$2.5 billion (changed N/A YoY), while the FY2025 annual figure was $3.1 billion, changed N/A from the prior year.
- Retained Earnings for Q1 2026 stood at -$2.5 billion, down from $3.1 billion in the prior quarter.
- The five-year high for Retained Earnings was $3.1 billion in Q4 2025, with the low at -$2.5 billion in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn | 3.14 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.14 Bn |
| Mar 31, 2026 | -2.55 Bn |
| Dec 31, 2025 | 3.14 Bn |
| Sep 30, 2025 | 748,000.00 |
| Jun 30, 2025 | 3.12 Bn |